Regasta™

[Itopride HCl]

رگیستا

50mg Tablets

DESCRIPTION
Regasta (Itopride HCl) is a prokinetic benzamide derivative. It inhibits dopamine and have a gastrokinetic effect.
Chemically, Itopride HCl is N-[4-[2-(Dimethylamino) ethoxy]benzyl]-3,4-dimethoxybenzamide monohydrochloride. Its molecular formula is $C_{20}H_{26}N_2O_4$.HCl and the structural formula is:



Itopride HCl

QUALITATIVE & QUANTITATIVE COMPOSITION
Regasta (Itopride HCl) is available for oral administration as:

Regasta Tablets 50mg
Each film-coated tablet contains:
Itopride HCl... 50mg

CLINICAL PHARMACOLOGY
Mechanism of Action
Itopride HCl increases the release of acetylcholine through dopamine D_2-receptor antagonistic activity and inhibits decomposing released acetylcholine through its acetylcholine esterase (AChE) inhibitory action, resulting in enhancement of gastrointestinal activity. Higher acetylcholine increases GI peristalsis, increases the lower oesophageal sphincter pressure, stimulates gastric motility, accelerates gastric emptying and improves gastro-duodenal coordination.

PHARMACOKINETICS
Absorption
Itopride HCl is rapidly and almost completely absorbed from the gastrointestinal tract. Relative bioavailability is calculated to be 60% due to liver first pass metabolism. Peak plasma levels (C_{max} 0.28 g/mL) are reached after 0.5-0.75 hr after 50mg of itopride HCl. Following multiple oral doses ranging from 50-200 mg 3 times daily, itopride HCl and its metabolites showed linear pharmacokinetics over a treatment period of 7 days, with minimal accumulation.

Distribution
Approximately 96% of itopride HCl is bound to plasma proteins. Albumin accounts for most of the binding. α1-acid glycoprotein accounts for <15% of binding.

Metabolism
Itopride HCl undergoes extensive hepatic metabolism in humans. Three metabolites have been identified, of which only one exerts minor activity without pharmacological relevance (approximately 2-3% of that of itopride HCl). The primary metabolite in humans is the N-oxide generated by oxidation of the tertiary amine N-dimethyl group. Itopride HCl is metabolized by a flavin-dependent monooxygenase (FMO3).

Excretion:
Itopride HCl and its metabolites are primarily excreted in the urine. The urinary excretions of itopride HCl and its N-oxide were 3.7% and 75.4%, respectively, after oral administration of a single therapeutic dose. The terminal phase half-life of itopride HCl is approximately 6 hrs.

Special Populations
Children:
Safety of itopride HCl in children <16 years has not been established.

Elderly:
Appropriate caution should be exercised in the administration and monitoring of itopride HCl in elderly patients reflecting the greater frequency of decreased hepatic, renal function and of concomitant disease or other drug therapy.

Patients with fish odor syndrome:
The abundance and efficiency of the human FMO-isozymes can be subject to genetic polymorphisms, which can lead to a rare autosomal recessive condition known as trimethylaminuria. Therefore, the half-life of itopride HCl may be longer in trimethylaminuria (fish odor syndrome) patients.

THERAPEUTIC INDICATIONS
Regasta (Itopride HCl) Tablet is used in the treatment of gastrointestinal symptoms of:
- Functional Dyspepsia
- Non-ulcer Dyspepsia (chronic gastritis) i.e.
  - Sensation of bloating,
  - Early satiety,
  - Upper abdominal pain or discomfort,
  - Anorexia,
  - Heartburn,
  - Nausea and
  - Vomiting.

DOSAGE & ADMINISTRATION
The usual adult dosage for oral use is 150 mg of Regasta (Itopride HCl) daily in three divided doses before meals. The dose may be reduced according to patient's age and symptoms.

ADVERSE REACTIONS
The following adverse events have been reported in patients receiving itopride HCl:
Blood and Lymphatic System Disorders: Leukopenia and thrombocytopenia.
Immune System Disorders: Anaphylactoid reaction.
Endocrine Disorders: Increased prolactin level and gynecomastia.
Nervous System Disorders: Dizziness, headache and tremor.
Gastrointestinal Disorders: Diarrhea, constipation, abdominal pain, increased saliva, and nausea.
Hepatobiliary Disorder: Jaundice.
Skin and Subcutaneous Tissue Disorders: Rash, redness and itching.
Investigations: Increased AST (SGOT), increased ALT (SGPT), increased ϒ-GTP, increased alkaline phosphatase and increased bilirubin.

CONTRAINDICATIONS
Itopride HCl is contraindicated in:
- Patients with known hypersensitivity to itopride HCl or any of the excipient of the product.
- Patients in whom an increase in gastrointestinal motility could be harmful e.g., gastrointestinal hemorrhage, mechanical obstruction or perforation.

PRECAUTIONS
- Itopride HCl should be used with caution since it enhances the action of acetylcholine. Also, caution is advised in treatment of patients suffering from Parkinson's disease and conditions involving dopamine regulation issues.
- Itopride HCl should not be used aimlessly for a long term when no improvement of gastrointestinal symptoms is observed.

Pregnancy and Nursing Mothers
Itopride HCl should be used in pregnant women or in women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment. The safety of itopride HCl in pregnant women has not been established. It is ideal not to use itopride HCl in women during lactation, but if it is necessary, breast feeding should be avoided during the treatment of itopride HCl.

Drug Interactions
- Itopride HCl has gastrokinetic effects, therefore, it could influence the absorption of concomitantly orally administered drugs. Particular caution should be taken with drugs with a narrow therapeutic index, sustained-release or enteric-coated formulations.
- Concomitant administration with anticholinergic drugs e.g. Tiquizium bromide, scopolamine butyl bromide, timepidium bromide, etc. may reduce the action of itopride HCl.

OVERDOSAGE
There have been no reported cases of overdose in humans. In case of excessive overdose, the usual measures of gastric lavage and symptomatic therapy should be applied.

STORAGE
Store at 25°C (Excursions permitted between 15°C-30°C).
Protect from sunlight and moisture.
The expiration date refers to the product correctly stored at the required conditions.

HOW SUPPLIED
Regasta (Itopride HCl) Tablets 50mg are available in blister packs of 10's.

Keep out of reach of children.

To be sold on prescription of a registered medical practitioner only.

Please read the contents carefully before use.
This package insert is continually updated from time to time.

Manufactured by:
Getz pharma (PVT) LIMITED
www.getzpharma.com
29-30/27, K.I.A., Karachi, Pakistan
L-200007953